Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model

Microbiology and Immunology

Volumn 59, Issue 1, 2015, Pages 1-12

  Kawahara, Tomohiro ^a,b   Takahashi, Tadanobu ^a   Oishi, Kenta ^a   Tanaka, Hiromu ^a   Masuda, Midori ^a   Takahashi, Shunsaku ^a   Takano, Maiko ^a   Kawakami, Tatsuya ^a   Fukushima, Keijo ^a   Kanazawa, Hiroaki ^a   Suzuki, Takashi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Biofermin Kobe Research Institute   (Japan)

Author keywords

Bifidobacterium longum; Influenza virus; Natural killer cell; Probiotics

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; SULFALENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM MM 2; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; FEMALE; GENE EXPRESSION; HOST RESISTANCE; INFLUENZA A (H1N1); INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INNATE IMMUNITY; LUNG ALVEOLUS CELL; LYMPHOCYTE ACTIVATION; MORTALITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PEYER PATCH; RESPIRATORY TRACT INFLAMMATION; SPLEEN CELL; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; BIOSYNTHESIS; DISEASE MODEL; GENE EXPRESSION PROFILING; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); LUNG; ORAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; SPLEEN; SURVIVAL;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; INFECTIOUS FLACHERIE VIRUS; MURINAE; MUS; ORTHOMYXOVIRIDAE;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; INFLUENZA A VIRUS, H1N1 SUBTYPE; KILLER CELLS, NATURAL; LUNG; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PROBIOTICS; SPLEEN; SULFALENE; SURVIVAL ANALYSIS;

EID: 84927741155     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12210     Document Type: Article

References (49)

1. FAO/WHO., (2001) The joint FAO/WHO expert consultation on evaluation of health and nutrition properties of probiotics in food held in Córdoba, Argentina from 1- 4 October, 2001. FAO, Rome and WHO, Geneva.
2. Philippe D., Heupel E., Blum-Sperisen S., Riedel C.U. ( 2011) Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol 149: 45-9.
3. Ohno H., Tsunemine S., Isa Y., Shimakawa M., Yamamura H. ( 2005) Oral administration of Bifidobacterium bifidum G 9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull 28: 1462-6.
4. Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., Tobe T., Clarke J.M., Topping D.L., Suzuki T., Taylor T.D., Itoh K., Kikuchi J., Morita H., Hattori M., Ohno H. ( 2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-7.
5. Ventola H., Lehtoranta L., Madetoja M., Simonen-Tikka M.L., Maunula L., Roivainen M., Korpela R., Holma R. ( 2012) Effects of the viability of Lactobacillus rhamnosus GG on rotavirus infection in neonatal rats. World J Gastroenterol 18: 5925-31.
6. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. ( 2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-86.
7. Wada T., Morishima T., Okumura A., Tashiro M., Hosoya M., Shiomi M., Okuno Y. ( 2009) Differences in clinical manifestations of influenza-associated encephalopathy by age. Microbiol Immunol 53: 83-8.
8. Culley F.J. ( 2009) Natural killer cells in infection and inflammation of the lung. Immunology 128: 151-63.
9. Stein-Streilein J., Guffee J. ( 1986) In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. J Immunol 136: 1435-41.
10. Tregoning J.S., Schwarze J. ( 2010) Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23: 74-98.
11. Hori T., Kiyoshima J., Shida K., Yasui H. ( 2002) Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. Clin Diagn Lab Immunol 9: 105-8.
12. Takeda S., Takeshita M., Kikuchi Y., Dashnyam B., Kawahara S., Yoshida H., Watanabe W., Muguruma M., Kurokawa M. ( 2011) Efficacy of oral administration of heat-killed probiotics from Mongolian dairy products against influenza infection in mice: alleviation of influenza infection by its immunomodulatory activity through intestinal immunity. Int Immunopharmacol 11: 1976-83.
13. Villena J., Chiba E., Tomosada Y., Salva S., Marranzino G., Kitazawa H., Alvarez S. ( 2012) Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immuno 13: 53.
14. Kiso M., Takano R., Sakabe S., Katsura H., Shinya K., Uraki R., Watanabe S., Saito H., Toba M., Kohda N., Kawaoka Y. ( 2013) Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3: 1563.
15. Iwabuchi N., Xiao J.Z., Yaeshima T., Iwatsuki K. ( 2011) Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. Biol Pharm Bull 34: 1352-5.
16. Groeger D., O'mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B., Shanahan F., Quigley E.M. ( 2013) Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4: 325-39.
17. Suzuki T., Sometani A., Yamazaki Y., Horiike G., Mizutani Y., Masuda H., Yamada M., Tahara H., Xu G., Miyamoto D., Oku N., Okada S., Kiso M., Hasegawa A., Ito T., Kawaoka Y., Suzuki Y. ( 1996) Sulphatide binds to human and animal influenza A viruses, and inhibits the viral infection. Biochem J 318 (Pt 2): 389-93.
18. Matrosovich M., Matrosovich T., Garten W., Klenk H.D. ( 2006) New low-viscosity overlay medium for viral plaque assays. Virol J 3: 63.
19. Takahashi T., Moriyama Y., Ikari A., Sugatani J., Suzuki T., Miwa M. ( 2008) Surface localization of the nuclear receptor CAR in influenza A virus-infected cells. Biochem Biophys Res Commun 368: 550-5.
20. Takahashi T., Murakami K., Nagakura M., Kishita H., Watanabe S., Honke K., Ogura K., Tai T., Kawasaki K., Miyamoto D., Hidari K.I., Guo C.T., Suzuki Y., Suzuki T. ( 2008) Sulfatide is required for efficient replication of influenza A virus. J Virol 82: 5940-50.
21. Takahashi T., Kurebayashi Y., Ikeya K., Mizuno T., Fukushima K., Kawamoto H., Kawaoka Y., Suzuki Y., Suzuki T. ( 2010) The low-pH stability discovered in neuraminidase of 1918 pandemic influenza A virus enhances virus replication. PLoS One 5: e15556.
22. Takahashi T., Takaguchi M., Kawakami T., Suzuki T. ( 2013) Sulfatide regulates caspase-3-independent apoptosis of influenza A virus through viral PB1-F2 protein. PLoS One 8: e61092.
23. Takaguchi M., Takahashi T., Hosokawa C., Ueyama H., Fukushima K., Hayakawa T., Itoh K., Ikeda K., Suzuki T. ( 2011) A single amino acid mutation at position 170 of human parainfluenza virus type 1 fusion glycoprotein induces obvious syncytium formation and caspase-3-dependent cell death. J Biochem 149: 191-202.
24. Neff-Laford H.D., Vorderstrasse B.A., Lawrence B.P. ( 2003) Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol 226: 54-64.
25. El Bakkouri, Descamps K., De Filette F., Smet M., Festjens A., Birkett E., Van Rooijen A., Verbeek N., Fiers S., Saelens W. ( 2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186: 1022-31.
26. He X.S., Draghi M., Mahmood K., Holmes T.H., Kemble G.W., Dekker C.L., Arvin A.M., Parham P., Greenberg H.B. ( 2004) T cell-dependent production of IFN-γ by NK cells in response to influenza A virus. J Clin Invest 114: 1812-9.
27. Orange J.S., Biron C.A. ( 1996) An absolute and restricted requirement for IL-12 in natural killer cell IFN-γ production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol 156: 1138-42.
28. Liu B., Mori I., Hossain M.J., Dong L., Takeda K., Kimura Y. ( 2004) Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 85: 423-8.
29. Wang K.S., Frank D.A., Ritz J. ( 2000) Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95: 3183-90.
30. Sareneva T., Julkunen I., Matikainen S. ( 2000) IFN-α and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol 165: 1933-8.
31. Weiss I.D., Wald O., Wald H., Beider K., Abraham M., Galun E., Nagler A., Peled A. ( 2010) IFN-γ treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interferon Cytokine Res 30: 439-49.
32. Brandstadter J.D., Yang Y. ( 2011) Natural killer cell responses to viral infection. J Innate Immun 3: 274-9.
33. Beli E., Clinthorne J.F., Duriancik D.M., Hwang I., Kim S., Gardner E.M. ( 2011) Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mech Ageing Dev 132: 503-10.
34. Zhang Y., Wallace D.L., De Lara C.M., Ghattas H., Asquith B., Worth A., Griffin G.E., Taylor G.P., Tough D.F., Beverley P.C., Macallan D.C. ( 2007) In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121: 258-65.
35. Fang M., Roscoe F., Sigal L.J. ( 2010) Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking. J Exp Med 207: 2369-81.
36. Camous X., Pera A., Solana R., Larbi A. ( 2012) NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol 2012: Article ID 195956, 8 pages.
37. Rink L., Cakman I., Kirchner H. ( 1998) Altered cytokine production in the elderly. Mech Ageing Dev 102: 199-209.
38. Borrego F., Alonso M.C., Galiani M.D., Carracedo J., Ramirez R., Ostos B., Pena J., Solana R. ( 1999) NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 34: 253-65.
39. Chiaretti A., Pulitano S., Barone G., Ferrara P., Romano V., Capozzi D., Riccardi R. ( 2013) IL-1β and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators Inflamm 2013: Article ID 495848, 8 pages.
40. Yu X., Zhang X., Zhao B., Wang J., Zhu Z., Teng Z., Shao J., Shen J., Gao Y., Yuan Z., Wu F. ( 2011) Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS One 6: e28680.
41. Hayden F.G., Fritz R., Lobo M.C., Alvord W., Strober W., Straus S.E. ( 1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 101: 643-9.
42. Estella A. ( 2011) Cytokine levels in bronchoalveolar lavage and serum in 3 patients with 2009 Influenza A(H1N1) v severe pneumonia. J Infect Dev Ctries 5: 540-3.
43. Sakai S., Kawamata H., Mantani N., Kogure T., Shimada Y., Terasawa K., Sakai T., Imanishi N., Ochiai H. ( 2000) Therapeutic effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice. J Virol 74: 2472-6.
44. Lin Y.P., Thibodeaux C.H., Pena J.A., Ferry G.D., Versalovic J. ( 2008) Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis 14: 1068-83.
45. Hoffmann E., Ashouri J., Wolter S., Doerrie A., Dittrich-Breiholz O., Schneider H., Wagner E.F., Troppmair J., Mackman N., Kracht M. ( 2008) Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway. J Biol Chem 283: 12120-8.
46. Ramana C.V., Cheng G.S., Kumar A., Kwon H.J., Enelow R.I. ( 2009) Role of alveolar epithelial early growth response-1 (Egr-1) in CD8+ T cell-mediated lung injury. Mol Immunol 47: 623-31.
47. Ichimiya I., Kawauchi H., Fujiyoshi T., Tanaka T., Mogi G. ( 1991) Distribution of immunocompetent cells in normal nasal mucosa: comparisons among germ-free, specific pathogen-free, and conventional mice. Ann Otol Rhinol Laryngol 100: 638-42.
48. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., Van Breda Vriesman, Sminia P.J. ( 1992) The role of nasopharyngeal lymphoid tissue. Immunol Today 13: 219-24.
49. Ruane D., Brane L., Reis B.S., Cheong C., Poles J., Do Y., Zhu H., Velinzon K., Choi J.H., Studt N., Mayer L., Lavelle E.C., Steinman R.M., Mucida D., Mehandru S. ( 2013) Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med 210: 1871-88.